Sarcomas

ADCT-601-102

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.
  • Open at Paris since : 19/07/2024
  • Target : Adult
  • Phase : Phase I

Trial description

Identify recommended phase 2 dose (RP2D) and/or maximum;tolerated dose (MTD), and characterize the safety and tolerability;of ADCT-601 monotherapy and in combination with gemcitabine.
Url of the trial

Main investigator